Figure 7
Thirty-three sensitive CYP3A substrates identified in the DIDB. Drugs that are underlined were listed in the latest FDA draft guidance [6]. The sensitive substrates are presented in three quadrants, based on their AUCR (# in brackets) when co-administered with a known CYP3A inhibitor.